Arsenic-based therapy shown to help eradicate leukemia-initia... (ML by As2O3 successfully disrupted LICs ...)

Arsenic-based therapy shown to help eradicate leukemia-initiating cells

Date:5/12/2008

ML by As2O3 successfully disrupted LICs, increasing the efficacy of the anti-cancer therapy by sensitizing the LICs to pro-apoptopic stimuli.

Its actually a very simple concept, says Pandolfi. Ninety percent of existing cancer treatments are antiproliferative agents they target the pool of proliferative cells, leaving behind the dormant LICs.

But in determining that PML serves to guard the LICs that have been left behind, we also discovered that if we knock out PML [through pharmacologic means], the LICs will lose their braking abilities and run out of gas, thereby commiting the fatal error of proliferation -- and exposing themselves to the deadly effects of cancer therapies.

Pandolfis laboratory is now trying to determine whether PML exerts a similar role in the stem cells of other tissues, as well as in the cancer initiating cells of solid tumors.

If this turn out to be the case, he adds, the transient use of As2O3 may represent a more global strategy to target CICs in other forms of cancer.

'/>"/>

Contact: Bonnie Prescott
bprescot@bidmc.harvard.edu
617-667-7306
Beth Israel Deaconess Medical Center
Source:Eurekalert

0

GOOD

Page: 1 2 3
Related medicine news :

1. FDA Says, Wait To Dying Men; Coast-To-Coast Prostate Cancer Demonstrations on May 30th in Protest of FDA Failure to Approve Safe, Effective Immunotherapy
2. Skin flaps deliver cancer-fighting therapy, ASPS study reveals
3. UAB first in US to offer speedier precise cancer radiotherapy
4. Virtual Reality Therapy May Help PTSD Patients
5. Kidney disease worsens in a fourth of African-Americans despite therapy for hypertension
6. Leveraging CVIS Integration to Automate Anticoagulation Therapy Webinar
7. New OPAL Therapy presents simple, cost-effective method of treating HIV infection
8. Promising early evidence of the superior benefits of drug therapy for diabetic eye disease
9. American Humane Forms Human-Animal Bond Division, Including Animal-Assisted Therapy, Humane Ed and Pets & Womens Shelters
10. Immune-Boosting Lung Cancer Therapy Shows Promise
11. Varian Medical Systems Announces Record Demand for New RapidArc(TM) Radiotherapy Treatment Capability

Post Your Comments:

(Date:5/23/2013)... high-risk neuroblastoma a common tumor that forms in the ... drugs. A study published by Cell Press in the ... reveals a new genomic approach to screen for compounds ... to differentiate, or convert from immature cells to more ... identified a compound that causes neuroblastoma cells to differentiate, ...

(Date:5/23/2013)... 2013 Sika Sarnafil , the ... today announced Imperial Roof Systems of Iowa as the ... dedication to quality during the re-roofing of the SuperTarget ... a Sika Sarnafil Elite contractor and one of Target’s ... is committed to sustainable building practices and they are ...

(Date:5/23/2013)... 23, 2013 Diabetes is one of ... become a nuisance when patients are unfortunate enough to ... the National Diabetes Information Clearinghouse at http://goo.gl/QyhCz , ... risk of developing neuropathy which further shrivels the nervous ... such patients. Such nerve damage affects the whole body ...

(Date:5/23/2013)... May 23, 2013 Professional Insurance Plans, ... the nation to celebrate Fibromyalgia Education and Awareness Month. ... chiropractors across the country, the agency feels that it ... of this syndrome that affects an estimated 10 million ... Association , the definition of Fibromyalgia (FM) is, “a ...

(Date:5/23/2013)... 2013 Retül University , the ... announce the formation of a strategic educational partnership with ... to offer a bike industry first “Positioned for Speed” ... for time trial, road and triathlon bike fit. , ... bike fitters with a Retül University, F.I.S.T. or S.I.C.I ...

Breaking Medicine News(10 mins):Health News:New screening approach uncovers potential alternative drug therapies for neuroblastoma 2 Health News:Sika Sarnafil Announces Recycling Project of the Year Winner 2 Health News:Neuropathy Nerve Damage Can Now Be Reversed With Neuracel 2 Health News:Professional Insurance Plans Encourages the Nation to Celebrate Fibromyalgia Education and Awareness Month 2 Health News:Retül, Ero Sports and Alphamantis Partner for Industry First Aero Fit Course 2 Health News:Retül, Ero Sports and Alphamantis Partner for Industry First Aero Fit Course 3

[0] New screening approach uncovers potential alternative drug therapies for neuroblastoma [0] Sika Sarnafil Announces Recycling Project of the Year Winner [0] Neuropathy Nerve Damage Can Now Be Reversed With Neuracel [0] Professional Insurance Plans Encourages the Nation to Celebrate Fibromyalgia Education and Awareness Month [0] Retül, Ero Sports and Alphamantis Partner for Industry First Aero Fit Course

... Mark,s Breathe Easy Tour, Inspires Those with Chronic Lung Disease to ... ... SAN DIEGO, July 24 SeQual Technologies Inc. (SeQual),announced today the ... the American Lung,Association of California and Seton Medical Center intended to ...

... PALO ALTO, Calif., July 24 Horizon Therapeutics, ... Timothy P.,Walbert has been named president, chief executive ... Horizon Therapeutics., "Tim has a long, proven ... the pain and arthritis areas," said George,Tidmarsh, M.D., ...

... Free Diabetes Education and Cholesterol ... Screenings to Race Spectators, INDIANAPOLIS, Ind., July ... and Polymer Technology Systems,Inc. as a partner in the recently announced ... as cholesterol,screenings at the IndyCar Series during the 2008 racing season., ...

... $0.51 from $0.38 in ... - Record diluted EPS increased 30.2 percent to $0.56 from $0.43 in, second-quarter 2007, excluding ... from the ... - Specialty revenues increased 32.6 percent to a record of nearly $2.0 ...

... Mass., July 24 Tepha, Inc., a developer ... resorbable polymers, announced,today that it has appointed John ... and Chief Operating Officer. Mr. Hartnett joins Tepha,following ... which he,progressed from field sales, to marketing management, ...

... BEIJING, July 24 /Xinhua-PRNewswire-FirstCall/ -- China Medical,Technologies, ... a leading China-based,medical device company that develops, ... high intensity focused ultrasound tumor,therapy systems, today ... results for the first quarter ended June ...

SeQual Technologies, American Lung Association of California and Seton Medical Center Partner to Support Survivor & Cyclist in 500-Mile California Ride Horizon Therapeutics Names Timothy P. Walbert as President and CEO Eli Lilly and Company and Vision Racing Sponsor Vision Wellness Tour at the IndyCar Series Across the Country Medco Reports Record Second-Quarter 2008 GAAP Diluted EPS; Reflects Growth of 34.2 Percent; Raises and Narrows 2008 Guidance Tepha Announces Appointment of John Hartnett as Executive Vice President and Chief Operating Officer China Medical Technologies to Announce Financial Results for the First Quarter Ended June 30, 2008 on August 4, 2008

(Date:5/23/2013)... , May 23, 2013 Isis Pharmaceuticals, Inc. ... today announced that management will present a company overview at ... Conference on Thursday, May 30, 2013 at 8:40 a.m. ET ... live audio webcast of the presentation will be available on ... www.isispharm.com . A replay will be available on the ...

(Date:5/23/2013)... TUCSON, Ariz. , May 23, 2013 ... world,s first and only FDA, Health Canada and CE ... announced today that the Glasgow Science Centre in ... visitors annually, is featuring the SynCardia temporary Total ... as part of its $3 million Bodyworks Exhibition, one ...

(Date:5/23/2013)... , May 23, 2013 BioLife Solutions , ... proprietary clinical grade hypothermic storage and ... contract aseptic media manufacturer , today announced its ... Regenerative Medicine Congress 2013 this week in ... ) Dr. Aby J. Mathew, BioLife,s Senior ...

Breaking Medicine Technology:Isis Pharmaceuticals to Present at the Deutsche Bank 38th Annual dbAccess Health Care Conference 2 Glasgow Science Centre Features SynCardia Total Artificial Heart in $3 Million Exhibition 2 Glasgow Science Centre Features SynCardia Total Artificial Heart in $3 Million Exhibition 3 BioLife Solutions Announces Presentation at 8th World Stem Cells & Regenerative Medicine Congress 2 BioLife Solutions Announces Presentation at 8th World Stem Cells & Regenerative Medicine Congress 3

[0] Isis Pharmaceuticals to Present at the Deutsche Bank 38th Annual dbAccess Health Care Conference [0] Glasgow Science Centre Features SynCardia Total Artificial Heart in $3 Million Exhibition [0] BioLife Solutions Announces Presentation at 8th World Stem Cells & Regenerative Medicine Congress

... - Results Highlight the Potential of ... Algeta ASA (OSE: ALGETA), the ... BC1-04 study reported today it has completed its,comprehensive phase ... for bone metastases in patients with hormone-refractory,prostate cancer (HRPC). ...

... After eight weeks of treatment, RAD001 halted tumor growth ... with chemotherapy - Based on these promising data, Novartis ... advanced gastric cancer patients- Gastric cancer is the second ... of new cases occurring in East AsiaEAST HANOVER, N.J., ...

Cached Medicine Technology:Algeta Completes Comprehensive Phase II Clinical Program With Alpharadin for Treating Bone Metastases in Patients With Advanced Prostate Cancer 2 Algeta Completes Comprehensive Phase II Clinical Program With Alpharadin for Treating Bone Metastases in Patients With Advanced Prostate Cancer 3 Algeta Completes Comprehensive Phase II Clinical Program With Alpharadin for Treating Bone Metastases in Patients With Advanced Prostate Cancer 4 Algeta Completes Comprehensive Phase II Clinical Program With Alpharadin for Treating Bone Metastases in Patients With Advanced Prostate Cancer 5 Algeta Completes Comprehensive Phase II Clinical Program With Alpharadin for Treating Bone Metastases in Patients With Advanced Prostate Cancer 6 RAD001 Phase II Trial Results Positive in Patients with Advanced Gastric Cancer After Failure of One or More Prior Treatments 2 RAD001 Phase II Trial Results Positive in Patients with Advanced Gastric Cancer After Failure of One or More Prior Treatments 3 RAD001 Phase II Trial Results Positive in Patients with Advanced Gastric Cancer After Failure of One or More Prior Treatments 4 RAD001 Phase II Trial Results Positive in Patients with Advanced Gastric Cancer After Failure of One or More Prior Treatments 5 RAD001 Phase II Trial Results Positive in Patients with Advanced Gastric Cancer After Failure of One or More Prior Treatments 6

Algeta Completes Comprehensive Phase II Clinical Program With Alpharadin for Treating Bone Metastases in Patients With Advanced Prostate Cancer RAD001 Phase II Trial Results Positive in Patients with Advanced Gastric Cancer After Failure of One or More Prior Treatments

... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...

... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...

... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...

Medicine Products:

Morphine Quantitation, Serum or Plasma Monoethylglycinerylidide, Urine Moricizine (Ethmozine), Serum or Plasma Mono/Dizygotic Differentiation